CSF tau correlates with CJD disease severity and cognitive decline

Acta Neurologica Scandinavica

Volumn 133, Issue 2, 2016, Pages 119-123

  Cohen, O S ^a,b   Chapman, J ^a,b   Korczyn, A D ^b   Warman Alaluf, N ^a   Nitsan, Z ^c   Appel, S ^c   Kahana, E ^c   Rosenmann, H ^d  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c BARZILAI MEDICAL CENTER   (Israel)

^d HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Cognitive decline; Creutzfeldt Jakob disease; E200K mutation; Tau protein

Indexed keywords

TAU PROTEIN;

ADULT; AGED; ARTICLE; ASSESSMENT OF HUMANS; CLINICAL ASSESSMENT; COGNITIVE DEFECT; CREUTZFELDT JAKOB DISEASE; CREUTZFELDT JAKOB DISEASE NEUROLOGICAL SCALE; DISEASE SEVERITY; EXPANDED DISABILITY STATUS SCALE; FAMILIAL CREUTZFELDT JAKOB DISEASE; FEMALE; FRONTAL ASSESSMENT BATTERY; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL PERFORMANCE; MINI MENTAL STATE EXAMINATION; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; NEUROLOGIST; PROTEIN CEREBROSPINAL FLUID LEVEL;

EID: 84953635630     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/ane.12441     Document Type: Article

References (39)

1. Prusiner SB. Molecular biology of prion diseases. Science 1991;252:1515-22.
2. Korczyn AD. Prion diseases. Curr Opin Neurol 1997;10:273-81.
3. Hsiao K, Meiner Z, Kahana E et al. Mutation of the prion protein in Libyan Jews with Creutzfeldt-Jakob disease. N Engl J Med 1991;324:1091-7.
4. WHO. Global surveillance, diagnosis and therapy of human transmissible spongiform encephalopathies: report of the WHO consultation. Geneva: World Health Organization. Emerging and other communicable diseases, surveillance and control, 1998.
5. Zerr I, Kallenberg K, Summers DM et al. Updated clinical diagnostic criteria for sporadic Creutzfeldt-Jakob disease. Brain 2009;132:2659-68.
6. Otto M, Wiltfang J, Cepek L et al. Tau protein and 14-3-3 protein in the differential diagnosis of Creutzfeldt-Jakob disease. Neurology 2002;58:192-7.
7. Ladogana A, Sanchez-Juan P, Mitrova E et al. Cerebrospinal fluid biomarkers in human genetic transmissible spongiform encephalopathies. J Neurol 2009;256:1620-8.
8. Otto M, Esselmann H, Schulz-Shaeffer W et al. Decreased beta-amyloid1-42 in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Neurology 2000;54:1099-102.
9. Mollenhauer B, Cullen V, Kahn I et al. Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Exp Neurol 2008;213:315-25.
10. Tapiola T, Alafuzoff I, Herukka SK et al. Cerebrospinal fluid β-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol 2009;66:382-9.
11. Rosenmann H. CSF biomarkers for amyloid and tau pathology in Alzheimer's disease. J Mol Neurosci 2012;47:1-14.
12. Van Everbroeck B, Quoilin S, Boons J, Martin JJ, Cras P. A prospective study of CSF markers in 250 patients with possible Creutzfeldt-Jakob disease. J Neurol Neurosurg Psychiatry 2003;74:1210-4.
13. Jimi T, Wakayama Y, Shibuya S et al. High levels of nervous system-specific proteins in cerebrospinal fluid in patients with early stage Creutzfeldt-Jakob disease. Clin Chim Acta 1992;211:37-46.
14. Boesenberg-Grosse C, Schulz-Schaeffer WJ, Bodemer M et al. Brain-derived proteins in the CSF: do they correlate with brain pathology in CJD? BMC Neurol 2006;6:35.
15. Fulbright RK, Hoffmann C, Lee H, Pozamantir A, Chapman J, Prohovnik I. MR imaging of familial Creutzfeldt-Jakob disease: a blinded and controlled study. AJNR Am J Neuroradiol 2008;29:1638-43.
16. Cyngiser TA. Creutzfeldt-Jakob disease: a disease overview. Am J Electroneurodiagnostic Technol 2008;48:199-208.
17. Folstein MF, Folstein SE, McHugh PR. Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-98.
18. Dubois B, Slachevsky A, Litvan I, Pillon B. The FAB: a Frontal Assessment Battery at bedside. Neurology 2000;55:1621-6.
19. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-52.
20. Lyden P, Brott T, Tilley B et al. Improved reliability of the NIH Stroke Scale using video training. NINDS TPA Stroke Study Group. Stroke 1994;25:2220-6.
21. Cohen OS, Prohovnik I, Korczyn AD et al. The Creutzfeldt-Jakob disease (CJD) neurological status scale: a new tool for evaluation of disease severity and progression in CJD. Acta Neurol Scand 2011;124:368-74.
22. Fortea J, Llad A, Bosch BA et al. Cerebrospinal fluid biomarkers in Alzheimer's disease families with PSEN1 mutations. Neurodegener Dis 2011;8:202-7.
23. Csernansky JG, Miller JP, McKeel D, Morris JC. Relationships among cerebrospinal fluid biomarkers in dementia of the Alzheimer type. Alzheimer Dis Assoc Disord 2002;16:144-9.
24. Lin YT, Cheng JT, Yao YC et al. Increased total tau but not amyloid-beta(42) in cerebrospinal fluid correlates with short-term memory impairment in Alzheimer's disease. J Alzheimers Dis 2009;18:907-18.
25. Ivanoiu A, Sindic CJ. Cerebrospinal fluid tau protein and amyloid beta42 in mild cognitive impairment: prediction of progression to Alzheimer's disease and correlation with the neuropsychological examination. Neurocase 2005;11:32-9.
26. Kanai M, Matsubara E, Isoe K et al. Longitudinal study of cerebrospinal fluid levels of tau, A beta1-40, and A beta1-42(43) in Alzheimer's disease: a study in Japan. Ann Neurol 1998;44:17-26.
27. Sämgård K, Zetterberg H, Blennow K, Hansson O, Minthon L, Londos E. Cerebrospinal fluid total tau as a marker of Alzheimer's disease intensity. Int J Geriatr Psychiatry 2005;25:403-10.
28. Stefani A, Martorana A, Bernardini S et al. CSF markers in Alzheimer disease patients are not related to the different degree of cognitive impairment. J Neurol Sci 2006;251:124-8.
29. Haldenwanger A, Eling P, Kastrup A, Hildebrandt H. Correlation between cognitive impairment and CSF biomarkers in amnesic MCI, nonamnesic MCI, and Alzheimer's disease. J Alzheimers Dis 2010;22:971-80.
30. Haense C, Buerger K, Kalbe E et al. CSF total and phosphorylated tau protein, regional glucose metabolism and dementia severity in Alzheimer's disease. Eur J Neurol 2008;15:1155-62.
31. Meiner Z, Kahana E, Baitcher F et al. Tau and 14-3-3 of genetic and sporadic Creutzfeldt-Jakob disease patients in Israel. J Neurol 2011;258:255-62.
32. Steinacker P, Weidehaas K, Cepek L, Feneberg E, Kretzschmar HA, Otto M. Influence of the blood-CSF-barrier function on s100B in neurodegenerative diseases. Acta Neurol Scand 2013;128:249-56.
33. Satoh K, Shirabe S, Eguchi H et al. 14-3-3 protein, total tau and phosphorylated tau in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease and neurodegenerative disease in Japan. Cell Mol Neurobiol 2006;26:45-52.
34. Hort J, Bartos A, Pirttilä T, Scheltens P. Use of cerebrospinal fluid biomarkers in diagnosis of dementia across Europe. Eur J Neurol 2010;17:90-6.
35. Mattsson N, Andreasson U, Persson S et al. CSF biomarker variability in the Alzheimer's Association quality control program. Alzheimers Dement 2013;9:251-61.
36. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991;82:239-59.
37. Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 1992;42:631-9.
38. Bierer LM, Hof PR, Purohit DP et al. Neocortical neurofibrillary tangles correlate with dementia severity in Alzheimer's disease. Arch Neurol 1995;52:81-8.
39. Tapiola T, Overmyer M, Lehtovirta M et al. The level of cerebrospinal fluid tau correlates with neurofibrillary tangles in Alzheimer's disease. Neuroreport 1997;8:3961-3.